RT Journal Article
SR Electronic
T1 Neutralization of VOCs including Delta one year post COVID-19 or vaccine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.12.21261951
DO 10.1101/2021.08.12.21261951
A1 Havervall, Sebastian
A1 Marking, Ulrika
A1 Gordon, Max
A1 Ng, Henry
A1 Greilert-Norin, Nina
A1 Lindbo, Sarah
A1 Blom, Kim
A1 Nilsson, Peter
A1 Phillipson, Mia
A1 Klingström, Jonas
A1 Mangsbo, Sara
A1 Åberg, Mikael
A1 Hober, Sophia
A1 Thålin, Charlotte
YR 2021
UL http://medrxiv.org/content/early/2021/08/15/2021.08.12.21261951.abstract
AB Background SARS-CoV-2 variants, such as Alpha, Beta, Gamma and Delta, are raising concern about the efficiency of neutralizing antibodies (NAb) induced by wild-type infection or vaccines based on the wild-type spike.Methods We determined IgG and NAb against SARS-CoV-2 variants one year following mild wild-type infection (n=104) and two-dose regimens with BNT162b2 (BNT/BNT) (n=67), ChAdOx1 (ChAd/ChAd) (n=82), or heterologous ChAdOx1 followed by BNT162b2 (ChAd/BNT) (n=116).Findings Wild type spike IgG and NAb remained detectable in 80% (83/104) of unvaccinated participants one year post mild infection. The neutralizing capacity was similar against wild type (reference), Alpha (0.95 (0.92-0.98) and Delta 1.03 (0.95-1.11) but significantly reduced against Beta (0.54 (0.48-0.60)) and Gamma 0.51 (0.44-0.61). Similarly, BNT/BNT and ChAd/ChAd elicited sustained capacity against Alpha and Delta (1.01 (0.78-1.31) and 0.85 (0.64-1.14)) and (0.96 (0.84-1.09) and 0.82 (0.61-1.10) respectively), with reduced capacity against Beta (0.67 (0.50-0.88) and 0.53 (0.40-0.71)) and Gamma (0.12 (0.06-0.27) and 0.54 (0.37-0.80)). A similar trend was found following ChAd/BNT (0.74 (0.66-0.83) and 0.70 (0.50-0.97) against Alpha and Delta and 0.29 (0.20-0.42) and 0.13 (0.08-0.20) against Beta and Gamma).Interpretation Persistent neutralization of the wide-spread Alpha and Delta variants one year after wild-type infection may aid vaccine policy makers in low-resource settings when prioritizing vaccine supply. The reduced capacity of neutralizing Beta and Gamma strains, but not the Alpha and Delta strains following both infection and three different vaccine regimens argues for caution against Beta and Gamma-exclusive mutations in the efforts to optimize next generation SARS-CoV-2 vaccines.Funding A full list of funding bodies that contributed to this study can be found in the Acknowledgements sectionCompeting Interest StatementSoH has participated on Astra Zeneca COVID-19 SCG Virtual Advisory Board. Otherwise, the authors declare no competing interests.Funding StatementThis work was funded by Jonas & Christina af Jochnick foundation; Lundblad family foundation; Region Stockholm; Knut and Alice Wallenberg foundation; Science for Life Laboratory (SciLifeLab); Erling-Persson family foundation; CIMED and the Swedish Research Council.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Swedish Ethical Review Authority (dnr 2020-01653), and written informed consent was obtained from all study participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe anonymized datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.